TY  - JOUR
A1  - Minckwitz, Gunter von
A1  - Harder, Sebastian
A1  - Hövelmann, Sascha
A1  - Jäger, Elke
A1  - Al-Batran, Salah-Eddin
A1  - Loibl, Sibylle
A1  - Atmaca, Akin
A1  - Cimpoiasu, Christian
A1  - Neumann, Antje
A1  - Abera, Aklil
A1  - Knuth, Alexander
A1  - Kaufmann, Manfred
A1  - Jäger, Dirk
A1  - Maurer, Alexander B.
A1  - Wels, Winfried S.
T1  - Correction: Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
N2  - Following publication of the data presented by von Minckwitz and colleagues [1] it has been brought to our attention that some patients should be scored differently. Stable disease was seen in three of the eighteen patients instead of two of the eighteen patients: one patient with transitional cell carcinoma treated at 4 micro g/kg scFv(FRP5)-ETA per day, and two breast cancer patients treated at 4 and 12.5 micro g/kg scFv(FRP5)-ETA per day. Disease progression occured in 9 of the eighteen patients evaluated (see corrected Table 2 overleaf). This does not affect the conclusions of our study. In addition we would like to correct the following errors: patient IDs for patients U01 and U02 in the original Table 2 were interchanged. In addition, patient N03 had a grade 3 elevation of gamma-glutamyl transferase, and not grade 2 (see corrected Table 2 overleaf). http://publikationen.ub.uni-frankfurt.de/volltexte/2005/1156/
Y1  - 2006
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/1036
UR  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:hebis:30-44520
N1  - s.a. http://publikationen.ub.uni-frankfurt.de/volltexte/2005/1156/

© 2006 BioMed Central Ltd
ER  -